Physician profile
Daniel A Herring
NPI 1528028990
$4,255.07
in general payments reported to CMS, 2019-2025
26 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $317 · 2023: $1,124 · 2024: $1,122 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,937.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $745.86 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $608.93 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $585.26 | 2022-2025 | |
| Novo Nordisk INC | $584.19 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $334.39 | 2023-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $213.84 | 2022-2025 | Aristada, Lybalvi |
| Corcept Therapeutics | $128.53 | 2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.60 | 2022-2025 | Jardiance |
| Amgen INC. | $115.41 | 2023-2025 | Evenity, Prolia |
| Abbott Laboratories | $109.68 | 2024-2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $94.78 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $78.90 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $67.05 | 2025 | Austedo Xr |
| Solta Medical, A Division of Bausch Health US, LLC | $65.45 | 2025 | Clear+Brilliant |
| Ucb, INC. | $57.81 | 2024-2025 | Briviact, Nayzilam |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49.40 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $46.67 | 2025 | Arexvy, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $44.58 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $44.53 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.14 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $36.18 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $20.00 | 2022 | |
| Pfizer INC. | $17.81 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $17.17 | 2023 | Eliquis |
| Astellas Pharma US INC | $14.43 | 2024 | Veozah |
| Philips North America LLC | $13.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.